Answers are grounded in this paper and cite their sources.
Review highlights complement pathways and therapeutic candidates in age-related macular degeneration, indicating opportunities and challenges for clinical intervention.
Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of complement pathways involved in AMD and their therapies correspondingly. Finally, we discuss the development of the therapeutics existed now. Also, we enclose a list of drugs undergoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: